Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × anetumab ravtansine × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Gastrointestinal 1 Breast 1

Conditions

Pancreatic Neoplasms 2 Triple Negative Breast Neoplasms 1 Thymoma 1 Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 2 Celecoxib 2 zimberelimab 1 regorafenib 1 pembrolizumab 1 fludarabine 1 entinostat 1 anetumab ravtansine 1 Psychiatric Rehabilitation 1 Gemcitabine 1 Fentanyl 1 FANG vaccine 1 Early Intervention, Educational 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed

BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡